No other single viscoelastic works for you in cataract surgery like Amvisc Plus Viscoelastic. It adds the plus of cohesive versatility for every stage of the cataract procedure.
Key Features & Benefits
Cohesive plus dispersive characteristics in one syringe
The "plus" of cohesive versatility, providing lasting chamber retention plus efficient removal at the end of the case
The flexibility that allows you to do what you want to do throughout the procedure, without the need for a second viscoelastic
Amvisc Plus Viscoelastic is molecularly engineered with a versatile range of cohesion that provides lasting chamber retention plus efficient removal at the end of the case. Cohesive versatility allows you to do what you want to do throughout the procedure, without needing a second viscoelastic.
Amvisc Plus Viscoelastic - Brief Statement
Amvisc and Amvisc Plus are indicated for use as surgical aids in ophthalmic anterior and posterior segment surgery including cataract extraction, intraocular lens (IOL) implantation, corneal transplantation and glaucoma filtering surgery, and surgical procedures to reattach the retina. Due to its lubricating and viscoelastic properties, transparency and ability to protect corneal endothelial cells, Amvisc and Amvisc Plus help maintain anterior chamber depth and visibility, minimizes interaction between tissues, and acts as a tamponade and vitreous substitute during retina reattachment surgery. Amvisc and Amvisc Plus also preserve tissue integrity and good visibility when used to fill the anterior and posterior segments of the eye following open sky procedures.
There are no contraindications to the use of Amvisc or Amvisc Plus when used as recommended as an intraocular implant.
Amvisc and Amvisc Plus viscoelastics are prepared from a biological source and the physician should be aware of the possible effects of using biological materials. Precautions normally considered during anterior segment and retinal attachment procedures are recommended.
An excess quantity of Amvisc or Amvisc Plus should not be used; Amvisc and Amvisc Plus should be removed from the anterior chamber at the end of surgery; and, if the postoperative intraocular pressure increases above expected values, correcting therapy should be administered.
There may be increased postoperative intraocular pressure due to pre-existing glaucoma or by the surgery itself
There have been isolated reports of particulates or haziness after the injection of Amvisc or Amvisc Plus. Particulates should be removed by irrigation and/or aspiration.
Transient postoperative inflammatory reactions; transient postoperative increase in intraocular pressure following use in anterior segment surgery; and, on rare occasions, postoperative reactions including inflammation, corneal edema and corneal decompensation.
- For health care professional use only -